Invicro Scientists Published in Science Translational Medicine
Invicro LLC, a Konica Minolta company and a leading provider of imaging biomarkers, core lab services and software for research and drug development, announces that the paper “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury1” has been published in Science Translational Medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190904005895/en/
Invicro scientists published in Science Translational Medicine (Graphic: Business Wire)
Invicro London scientists, Doctors Alex Whittington, Jan Passchier and Roger Gunn, are co-authors of this revolutionary study that uses positron emission tomography (PET) to understand tau pathology in traumatic brain injuries (TBI), years after they occur. The results illustrate that tau PET is an encouraging approach for measurement of progressive neurodegeneration associated with tauopathy following TBI.
“It was exciting to be part of this groundbreaking study with Dr. Nikos Gorgoraptis and Prof. David Sharp which shows that Tau PET imaging is an important biomarker for TBI and CTE,” stated Dr. Roger Gunn, EVP of Quantitative Data Sciences for Invicro and Professor of Molecular NeuroImaging at Imperial College London. “The advanced Tau analytics that were developed as part of this work further complement Invicro’s leading TauIQ analytics platform in Neurodegeneration.”
TBI can lead to life-long chronic neurodegeneration, including the possibility of dementia. The publication examines how the use of Flortaucipir ([18F]AV-1451, [18F]T807), a PET radioligand for tau, enables the examination of tau pathology in vivo in subjects who are long-term survivors of brain injuries. Flortaucipir has demonstrated potent and specific non-displaceable binding to tau neurofibrillary tangles in both post-mortem human brain tissue and brain scans of subjects with Alzheimer Disease. This study elegantly shows how tau signals can now also be detected in subjects suffering from brain injuries.
“Advanced analytical methods were required to produce these exciting findings and we are delighted that this work has been recognized by Science Translational Medicine, a journal that is known for publishing impactful and high-quality research,” stated Dr. Alex Whittington, PET and MRI Neuro-Imaging Analyst for Invicro.
Established in October 2009 by American Association for The Advancement of Science, Science Translational Medicine is a weekly journal focused on translational medicine and clinical research on human diseases. The journal seeks research that demonstrate significant and innovative progress toward the prevention, diagnosis, or treatment of disease in the field of translational medicine. Science Translational Medicine published “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury” on 4 September 2019 at 2 P.M. EST.
“Tau Imaging in neurodegenerative diseases, specifically TBI, is making significant strides,” stated Dr. Jan Passchier, EVP Global Head Laboratories and Clinics for Invicro. “The success of the research presented in this paper is undoubtedly a result of the combination of academic excellence of our esteemed collaborators and the operational and scientific strength Invicro has been able to bring to bear. I look forward to continuing our joint efforts in this important area in order to support disease understanding and enable development and objective testing of potential therapeutic strategies.”
1. “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury," Authors: Nikos Gorgoraptis, Lucia M. Li, Alex Whittington, Karl A. Zimmerman, Linda M. Maclean, Claire McLeod, Ewan Ross, Amanda Heslegrave, Henrik Zetterberg, Jan Passchier, Paul M. Matthews, Roger N. Gunn, Tom M. McMillan, David J. Sharp
About Invicro
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017. Now as part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, has inspired a strong and growing presence in the pre-clinical to late-phase clinical markets. For more information, visit www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190904005895/en/
Contact information
Amanda Harrell
VP, Global Marketing
media@invicro.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jefferies to Hold Asia Pacific Trading Day in Support of Australia Wildfires Relief on Wednesday January 2221.1.2020 07:00:00 CET | Press release
Jefferies confirmed that tomorrow, Wednesday, January 22nd, 2020, the firm will dedicate a day of trading to support relief efforts needed after the devastation caused by the recent wildfires taking place in Australia. As previously announced, Jefferies will donate net trading commissions on Wednesday, January 22 for all trading in Asia Pacific securities, including equities, fixed income and FX, by the firm’s clients globally. Simultaneously, all of the firm’s global employees will also be given the opportunity to personally donate to the relief effort. Jefferies will match all client trading commissions generated that day, as well as match all employee donations from across the firm. The total contribution will then be donated to relief organizations directly involved in the rescue and recovery efforts in Australia. Rich Handler, CEO, and Brian Friedman, President, of Jefferies commented: "All of us at Jefferies, including our many colleagues in Australia, 423 across Asia Pacific and
Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock21.1.2020 07:00:00 CET | Press release
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced today that it has entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein (sTREM-1). This agreement consolidates existing ties between Roche Diagnostics and Inotrem who are jointly developing since 2017 an in vitro assay for measurement of sTREM-1 in plasma samples of septic shock patients. Measurement of sTREM-1 in blood provides a valuable indicator for the severity and outcome prediction of septic shock patients. One of the main issues with septic shock is the heterogeneity of the patient population. The companion diagnostic test will allow a stratification of patients to identify those who are more likely to respond to Inotrem’s treatment. Septic shock is the ultimate complic
Call to Boost Collaborative Efforts to Save Lives by Reaching Seasonal Influenza Vaccination Targets Across the EU (Vaccines Europe) 21.1.2020 06:35:00 CET | Press release
At an event held in the European Parliament today, policymakers noted the lack of progress made by EU Member States towards the EU’s 75% target for seasonal influenza vaccination coverage rates among older-age and at-risk groupsi, first adopted in the EU Council Recommendation on seasonal influenza vaccination in 2009.ii Speakers from the European Commission, European Parliament, European Centre for Disease Prevention and Control (ECDC) and World Health Organisation (WHO) all agreed on the need to seize the opportunity presented by the 10-year milestone of the 2009 Recommendation to renew efforts to boost coverage rates and address the major public health challenges associated with seasonal influenza. Building on a new study on public perceptions of seasonal influenza disease and vaccination in four EU countriesiii and leveraging some national best practices, panellists stressed the need for all influenza stakeholders to gather in simultaneously addressing influenza vaccine confidence,
Takeda Named Global Top 100 Most Sustainable Corporation for Fifth Year Running21.1.2020 05:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) is proud to be named in the Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the fifth consecutive year. Corporate Knights assesses more than 7,300 companies against 21 key performance indicators. It uses these indicators to determine the top 1% most sustainable companies in the world, which are announced annually at the World Economic Forum in Davos, Switzerland. “Building sustainable value is a fundamental part of the way we do business at Takeda, and we are proud to be recognized as a global leader in sustainability,” said Christophe Weber, President and CEO. “This recognition by Corporate Knights is a testament to the strong foundation Takeda has laid and the progress we have already achieved. We remain steadfast in our commitment to realizing Better Health and a Brighter Future for all.” Corporate Knights highlighted Takeda’s performance in the following areas: Significan
Alibaba Cloud Named First Public Cloud Vendor in the World to Obtain Trusted Partner Network (TPN) Certification21.1.2020 02:00:00 CET | Press release
Alibaba Cloud, the data intelligence backbone of Alibaba Group, has today announced that it is the first public cloud vendor in the world to obtain the prestigious Trusted Partner Network (TPN) certification, an achievement that validates the entertainment industry’s confidence in its robust security and trustworthiness as a cloud service provider. With viewing consumption habits changing rapidly, broadcast platforms constantly evolving and new production techniques emerging globally, Alibaba Cloud is successfully helping the entertainment industry to revolutionise how it works in order to respond to and embrace these changing dynamics by offering a highly secure, dependable, flexible and scalable cloud-based platform. The TPN is a joint venture between two major entertainment industry associations; the Motion Picture Association of America (MPAA) and the Content Delivery & Security Association (CDSA). The TPN's goal is to help companies to ensure content security, prevent leaks, breac
Logitech Delivers Record Sales and Profitability in Holiday Quarter21.1.2020 02:00:00 CET | Press release
Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the third quarter of Fiscal Year 2020. Q3 sales were $903 million, up 4 percent in US dollars and 5 percent in constant currency, compared to Q3 of the prior year. Q3 GAAP operating income grew 4 percent to $129 million, compared to $123 million in the same quarter a year ago. Q3 GAAP earnings per share (EPS) grew 3 percent to $0.69, compared to $0.67 in the same quarter a year ago. Q3 non-GAAP operating income grew 6 percent to $152 million, compared to $143 million in the same quarter a year ago. Q3 non-GAAP EPS grew 6 percent to $0.84, compared to $0.79 in the same quarter a year ago. Cash flow from operations was $181 million, compared to $176 million in the same period a year ago. “We delivered our biggest quarter in sales and profit in company history, topping $900 million in quarterly sales for the first time ever,” said Bracken Darrell, Logitech president and chief executive officer. “Our th